双对应NaV毒素的功效和亚型选择性的变化是节点特异性的
Poanna Tran1, Hue N T Tran1, Kirsten L McMahon1
1Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia.
Bioconjugate chemistry
|June 1, 2023
概括
研究人员通过结合毒素和蜘蛛毒素创造了新的混合毒素,以准与疼痛相关的通道NaV1.7.7. 最好的混合物保持了强度,并显示了改变的选择性,突出显示了新的疼痛治疗药物的潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 富含二硫化物毒素是已知的电压导入通道亚型NaV1.7的抑制剂,是疼痛管理的关键目标.
- 开发强效和选择性的NaV1.7抑制剂对于有效的疼痛治疗来说至关重要.
研究的目的:
- 设计新的NaV1.7双价抑制剂,通过将孔毒素的孔隙阻断活性与蜘蛛毒素的门修饰活性相结合.
- 评估这些工程异体质毒素对人类NaV的强度和选择性1.7.7.
主要方法:
- 使用排序酶A或点击化学,将蜘蛛衍生的关门修饰剂 (例如,ProTx-II) 与μ-conotoxins (例如,SxIIIC) 结合起来.
- 对人类NaV1.7和其他通道亚型 (例如NaV1.4) 产生双价的强度和选择性的评估.
- 对突变和通道的分析,以确定每个毒素部分对整体活性的贡献.
主要成果:
- 与SxIIIC (Pro[LPATG6]Sx) 结合的混合ProTx-II保持了对hNaV1.7.7的本地ProTx-II的强度.
- 与hNaV1.4观察到协同效应,导致与母相比,亚型选择性发生变化.
- 检测发现,修饰剂毒素对双价的功效比孔隙阻断剂更有显著的贡献.
结论:
- 混合设计为开发具有量身定制功效和选择性的NaV1.7抑制剂提供了一个可行的策略.
- 这种方法为创建用于疼痛研究和治疗的新药学工具提供了机会和挑战.
- 了解毛孔阻塞剂和门修饰剂的不同作用是优化未来混合毒素设计的关键.
更多相关视频
相关概念视频
Fusion of Secretory Vesicles with the Plasma Membrane
11.2K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
11.2K
Dose-Response Relationship: Selectivity and Specificity
7.0K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
7.0K
Drug-Receptor Bonds
3.0K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
3.0K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
713
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
713
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
210
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
210


